Trial Profile
Phase I trial of the tolerability, pharmacodynamics and pharmacokinetics of MK 2206 in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Breast cancer; Neuroendocrine tumours; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck & Co
- 05 Nov 2010 New trial record.